HC Wainwright set a $27.00 target price on Paratek Pharmaceuticals (NASDAQ:PRTK) in a research note issued to investors on Monday morning, AnalystRatings.com reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
Several other analysts have also weighed in on PRTK. BTIG Research set a $36.00 price objective on Paratek Pharmaceuticals and gave the stock a sell rating in a report on Friday, November 1st. Zacks Investment Research lowered Paratek Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, October 24th. Finally, ValuEngine raised Paratek Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $20.42.
PRTK traded up $0.01 during midday trading on Monday, reaching $4.07. The company’s stock had a trading volume of 18,686 shares, compared to its average volume of 635,768. The stock has a market cap of $103.46 million, a P/E ratio of -1.14 and a beta of 1.74. The company has a fifty day simple moving average of $3.73 and a 200 day simple moving average of $4.04. The company has a current ratio of 12.17, a quick ratio of 11.83 and a debt-to-equity ratio of 14.48. Paratek Pharmaceuticals has a twelve month low of $2.66 and a twelve month high of $8.00.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported ($1.02) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.14. Paratek Pharmaceuticals had a negative return on equity of 459.96% and a negative net margin of 597.22%. The company had revenue of $2.05 million for the quarter, compared to analyst estimates of $1.86 million. Sell-side analysts expect that Paratek Pharmaceuticals will post -4.32 earnings per share for the current year.
In related news, insider Randall B. Brenner sold 7,674 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $3.98, for a total transaction of $30,542.52. Following the completion of the transaction, the insider now owns 91,338 shares in the company, valued at approximately $363,525.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Evan Loh sold 16,265 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $3.98, for a total value of $64,734.70. Following the transaction, the chief executive officer now owns 413,935 shares of the company’s stock, valued at approximately $1,647,461.30. The disclosure for this sale can be found here. Insiders have sold a total of 37,079 shares of company stock valued at $145,472 in the last 90 days. 7.70% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can lifted its position in shares of Paratek Pharmaceuticals by 503.1% during the 2nd quarter. Bank of Montreal Can now owns 7,816 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 6,520 shares during the period. Alambic Investment Management L.P. bought a new position in shares of Paratek Pharmaceuticals during the 2nd quarter worth approximately $82,000. A.R.T. Advisors LLC bought a new position in shares of Paratek Pharmaceuticals during the 2nd quarter worth approximately $121,000. Susquehanna International Group LLP lifted its position in shares of Paratek Pharmaceuticals by 33.0% during the 2nd quarter. Susquehanna International Group LLP now owns 32,060 shares of the specialty pharmaceutical company’s stock worth $128,000 after buying an additional 7,960 shares during the period. Finally, Citadel Advisors LLC raised its position in Paratek Pharmaceuticals by 7.2% in the 2nd quarter. Citadel Advisors LLC now owns 114,250 shares of the specialty pharmaceutical company’s stock valued at $456,000 after purchasing an additional 7,639 shares during the last quarter. Institutional investors and hedge funds own 72.99% of the company’s stock.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Read More: Elliott Wave Theory
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.